Literature DB >> 12040046

Peroxynitrite inactivates the human dopamine transporter by modification of cysteine 342: potential mechanism of neurotoxicity in dopamine neurons.

Samuel U Park1, Jasmine V Ferrer, Jonathan A Javitch, Donald M Kuhn.   

Abstract

Peroxynitrite (ONOO(-)) has been implicated as a causative factor in dopamine neuronal damage resulting from exposure to methamphetamine and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), and it may be involved in the etiology of Parkinson's Disease. ONOO(-) causes a concentration-dependent and irreversible reduction in dopamine uptake by EM4 cells stably expressing the human dopamine transporter (hDAT). The effect of ONOO(-) is manifested as a reduction in V(max). Cysteine, dithiothreitol, glutathione, and N-acetyl-cysteine, reagents that interact directly with ONOO(-), prevent this inhibition, whereas a scavenger of hydroxyl radical (dimethylsulfoxide), hydrogen peroxide (catalase), and superoxide (superoxide dismutase) did not. Dopamine in the extracellular medium protects the hDAT from ONOO(-), whereas intracellular dopamine does not. Parachloromercuribenzoic acid and 2-aminoethyl methanethiosulfonate (MTSEA), which share with ONOO(-) the ability to modify cysteine sulfhydryls, also inhibit hDAT function. ONOO(-) treatment lowers cysteine-specific labeling of the hDAT by MTSEA-biotin, suggesting that ONOO(-) reacts with one or more cysteines in hDAT. A mutant of hDAT (X7C) in which all intracellular and extracellular loop cysteines were mutated was resistant to inhibition by ONOO(-). Sensitivity to ONOO(-) was restored in mutants of hDAT in which reduced cysteines were present only in the first (C135) and third (C342) intracellular loops (CD-DAT), or in which C342 alone had been reintroduced into X7C (X7C-M342C). These results indicate that the hDAT is inhibited by ONOO(-) through oxidation of cysteine 342. Our studies also substantiate the possibility that drugs known to decrease DAT function in vivo (e.g., methamphetamine and MPTP) may exert their effects through ONOO(-)-mediated oxidative stress.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12040046      PMCID: PMC6758823          DOI: 20026443

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  70 in total

Review 1.  What we can learn from the effects of thiol reagents on transport proteins.

Authors:  P R van Iwaarden; A J Driessen; W N Konings
Journal:  Biochim Biophys Acta       Date:  1992-08-14

2.  Peroxynitrite plays a role in methamphetamine-induced dopaminergic neurotoxicity: evidence from mice lacking neuronal nitric oxide synthase gene or overexpressing copper-zinc superoxide dismutase.

Authors:  S Z Imam; G D Newport; Y Itzhak; J L Cadet; F Islam; W Slikker; S F Ali
Journal:  J Neurochem       Date:  2001-02       Impact factor: 5.372

3.  Methamphetamine decreases mouse striatal dopamine transporter activity: roles of hyperthermia and dopamine.

Authors:  V Sandoval; G R Hanson; A E Fleckenstein
Journal:  Eur J Pharmacol       Date:  2000-12-15       Impact factor: 4.432

4.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

5.  [(123)I]beta-CIT SPECT imaging demonstrates reduced density of striatal dopamine transporters in Parkinson's disease and multiple system atrophy.

Authors:  A Varrone; K L Marek; D Jennings; R B Innis; J P Seibyl
Journal:  Mov Disord       Date:  2001-11       Impact factor: 10.338

6.  Symmetrical dimer of the human dopamine transporter revealed by cross-linking Cys-306 at the extracellular end of the sixth transmembrane segment.

Authors:  H Hastrup; A Karlin; J A Javitch
Journal:  Proc Natl Acad Sci U S A       Date:  2001-08-28       Impact factor: 11.205

Review 7.  Nitric oxide, mitochondria and neurological disease.

Authors:  S J Heales; J P Bolaños; V C Stewart; P S Brookes; J M Land; J B Clark
Journal:  Biochim Biophys Acta       Date:  1999-02-09

8.  Peroxynitrite-mediated oxidative protein modifications.

Authors:  H Ischiropoulos; A B al-Mehdi
Journal:  FEBS Lett       Date:  1995-05-15       Impact factor: 4.124

9.  Role of neuronal nitric oxide in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity.

Authors:  S Przedborski; V Jackson-Lewis; R Yokoyama; T Shibata; V L Dawson; T M Dawson
Journal:  Proc Natl Acad Sci U S A       Date:  1996-05-14       Impact factor: 11.205

10.  Methamphetamine neurotoxicity involves vacuolation of endocytic organelles and dopamine-dependent intracellular oxidative stress.

Authors:  J F Cubells; S Rayport; G Rajendran; D Sulzer
Journal:  J Neurosci       Date:  1994-04       Impact factor: 6.167

View more
  27 in total

1.  Nitric oxide inhibits uptake of dopamine and N-methyl-4-phenylpyridinium (MPP+) but not release of MPP+ in rat C6 glioma cells expressing human dopamine transporter.

Authors:  Bo-Jin Cao; Maarten E A Reith
Journal:  Br J Pharmacol       Date:  2002-12       Impact factor: 8.739

Review 2.  Preconditioning provides neuroprotection in models of CNS disease: paradigms and clinical significance.

Authors:  R Anne Stetler; Rehana K Leak; Yu Gan; Peiying Li; Feng Zhang; Xiaoming Hu; Zheng Jing; Jun Chen; Michael J Zigmond; Yanqin Gao
Journal:  Prog Neurobiol       Date:  2014-01-02       Impact factor: 11.685

Review 3.  Antioxidant gene therapy against neuronal cell death.

Authors:  Juliana Navarro-Yepes; Laura Zavala-Flores; Annadurai Anandhan; Fang Wang; Maciej Skotak; Namas Chandra; Ming Li; Aglaia Pappa; Daniel Martinez-Fong; Luz Maria Del Razo; Betzabet Quintanilla-Vega; Rodrigo Franco
Journal:  Pharmacol Ther       Date:  2013-12-12       Impact factor: 12.310

4.  Increased Vesicular Monoamine Transporter 2 (VMAT2; Slc18a2) Protects against Methamphetamine Toxicity.

Authors:  Kelly M Lohr; Kristen A Stout; Amy R Dunn; Minzheng Wang; Ali Salahpour; Thomas S Guillot; Gary W Miller
Journal:  ACS Chem Neurosci       Date:  2015-03-09       Impact factor: 4.418

5.  Early minocycline treatment prevents a decrease in striatal dopamine in an SIV model of HIV-associated neurological disease.

Authors:  Kelly A Meulendyke; Mikhail V Pletnikov; Elizabeth L Engle; Patrick M Tarwater; David R Graham; M Christine Zink
Journal:  J Neuroimmune Pharmacol       Date:  2011-12-27       Impact factor: 4.147

Review 6.  Nucleus accumbens invulnerability to methamphetamine neurotoxicity.

Authors:  Donald M Kuhn; Mariana Angoa-Pérez; David M Thomas
Journal:  ILAR J       Date:  2011

7.  Dopamine disposition in the presynaptic process regulates the severity of methamphetamine-induced neurotoxicity.

Authors:  Donald M Kuhn; Dina M Francescutti-Verbeem; David M Thomas
Journal:  Ann N Y Acad Sci       Date:  2008-10       Impact factor: 5.691

8.  Effects of the organochlorine pesticide methoxychlor on dopamine metabolites and transporters in the mouse brain.

Authors:  Rosemary A Schuh; Jason R Richardson; Rupesh K Gupta; Jodi A Flaws; Gary Fiskum
Journal:  Neurotoxicology       Date:  2009-03       Impact factor: 4.294

9.  Increases in cytoplasmic dopamine compromise the normal resistance of the nucleus accumbens to methamphetamine neurotoxicity.

Authors:  David M Thomas; Dina M Francescutti-Verbeem; Donald M Kuhn
Journal:  J Neurochem       Date:  2009-04-28       Impact factor: 5.372

10.  Selenocysteine confers resistance to inactivation by oxidation in thioredoxin reductase: comparison of selenium and sulfur enzymes.

Authors:  Gregg W Snider; Erik Ruggles; Nadeem Khan; Robert J Hondal
Journal:  Biochemistry       Date:  2013-07-31       Impact factor: 3.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.